Endo to Acquire BioSpecifics for ~ $540M

Shots: Endo to acquire all the outstanding shares of BioSpecifics for $88.50/ share in cash, making a total deal value of $540M. The transaction is expected to close in late 2020 while Endo expects to fund the transaction with cash on hand BioSpecifics receives a royalty stream related to Endo’s collagenase-based therapies, which include Xiaflex …

Endo to Acquire BioSpecifics for ~ $540M Read More »